In distinct contrast to the study performed by Thomas et al. [18], the results of the phase 2 study performed by Philip et al. did not support the activity in using B + E combination in treating advanced HCC patients who were naïve to anti-VEGF therapy. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.